Recursion Pharmaceuticals-a Earnings

Recursion Pharmaceuticals-a’s revenue fell -80.16% since last year same period to $5.18Mn in the Q3 2025. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated -72.91% fall in its revenue since last 3-months.

Recursion Pharmaceuticals-a’s net profit fell -69.59% since last year same period to $-162.25Mn in the Q3 2025. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 5.61% jump in its net profits since last 3-months.

Recursion Pharmaceuticals-a’s net profit margin fell -754.72% since last year same period to -3135.32% in the Q3 2025. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated -248.43% fall in its net profit margins since last 3-months.

Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 2.86% jump from last quarter’s estimates.

Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current year stand at -0.34.

Recursion Pharmaceuticals-a’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Recursion Pharmaceuticals-a has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.